TIDMKMK
Kromek Group PLC
12 September 2023
12 September 2023
Kromek Group plc
("Kromek" or the "Group")
Kromek detectors used in Spectrum Dynamics' new SPECT/CT
scanner
Next generation scanner sets new standards in energy range,
sensitivity and resolution
Kromek (AIM: KMK), a leading developer of radiation and
bio-detection technology solutions for the advanced imaging and
CBRN detection segments, is pleased to announce that one of its key
customers, Spectrum Dynamics Medical ("Spectrum Dynamics"), has
introduced the latest addition to its next generation digital
SPECT/CT imaging portfolio, the VERITON-CT 300, for higher energy
imaging, using Kromek's digital detectors.
Based on Spectrum Dynamics' digital SPECT/CT platform, the
VERITON-CT 300 Series' detector technology provides the benefits of
increased sensitivity and throughput for Nuclear Medicine clinical
applications capable of using imaging utilising up to 300 keV
high-energy isotopes. This allows for greater procedure efficiency
in most exam types, as well as simultaneous acquisition of
multi-energy peak isotopes commonly used in theranostic imaging
applications.
A SPECT scan (single-photon emission computed tomography) is the
technique of using nuclear medicine tomographic imaging techniques
with gamma rays to provide detailed 3D functional images of the
body. The SPECT/CT scanner combines the framework of the CT
anatomic scan with the functional information provided by nuclear
medicine imaging (SPECT scan). The images from each scan are then
fused together providing highly accurate anatomical detail in 3D,
allowing medical specialists to more accurately pinpoint the exact
location of any abnormality.
Cadmium zinc telluride ("CZT") is transforming the detector
technology used in medical imaging, leading to significantly
shortened exam scan times, lower radiation dose to the patient,
improved image quality and quantitative accuracy without
compromise. Kromek's high-performance digital detectors, combined
with Spectrum's 360-degree, wide-bore SPECT/CT scanner and its
advanced image reconstruction algorithms, increase the energy range
up to 300 keV to support the throughput demand of current and new
emerging nuclear medicine clinical applications that set a new
standard in patient care.
The 300 Series digital detector technology sets new standards
with a 2-4 times improvement in energy range, system sensitivity,
and energy resolution. These improvements will further shorten the
scan times associated with current analogue or state-of-the-art
digital technology. The VERITON-CT Series also eliminates the need
for collimator replacement further streamlining and simplifying
workflow for various procedure types.
Arnab Basu, CEO of Kromek Group, said: "We are delighted that
our CZT detectors have been integrated into Spectrum Dynamics'
VERITON-CT 300 SPECT/CT systems. This enables enhanced image
quality and breakthrough clinical capabilities in digital SPECT/CT.
Spectrum Dynamics has long been at the forefront of developing
next-generation SPECT/CT scanners to deliver better patient
outcomes, and we are pleased to be part of this significant advance
in nuclear medical imaging technology. There is real commercial
momentum in this area, as companies continue to realise the
significant benefits of CZT-based SPECT/CT systems, which is
driving widespread adoption. As the only commercial independent
global supplier of CZT, Kromek is well-placed to capitalise on this
large market opportunity."
Gilad Yoeli, CEO of Spectrum Dynamics, added: "Clinical users
across the world provide us with feedback on the Nuclear Medicine
challenges they face. Providing the technology to address such
challenges is what drives us. The increased sensitivity, improved
energy resolution, and broader energy range of Kromek's detector
technology make it the right choice for our customers' future
imaging platforms. To better meet the current and future needs of
SPECT imaging, Spectrum offers a full line of scanners, the 200 the
400 and now the 300, this offering allows nuclear medicine
departments to base their entire scanner fleet on advanced digital
detector technology."
Change of Name of Nominated Adviser and Broker
The Group also announces that its Nominated Adviser and Broker
has changed its name to Cavendish Capital Markets Limited following
completion of its own corporate merger.
For further information, please contact:
Kromek Group plc
Arnab Basu, CEO
Paul Farquhar, CFO +44 (0)1740 626 060
Cavendish Capital Markets Limited (Nominated
Adviser and Broker)
Geoff Nash/Giles Balleny/Seamus Fricker -
Corporate Finance
Tim Redfern/Charlotte Sutcliffe - ECM
Michael Johnson/Tamar Cranford-Smith - Sales +44 (0)20 7220 0500
Gracechurch Group (Financial PR)
Harry Chathli/Claire Norbury/Henry Gamble +44 (0)20 4582 3500
Kromek Group plc
Kromek Group plc is a leading developer of radiation detection
and bio-detection technology solutions for the advanced imaging and
CBRN detection segments. Headquartered in County Durham, UK, Kromek
has manufacturing operations in the UK and US, delivering on the
vision of enhancing the quality of life through innovative
detection technology solutions.
The advanced imaging segment comprises the medical (including CT
and SPECT), security and industrial markets. Kromek provides its
OEM customers with detector components, based on its core cadmium
zinc telluride (CZT) platform, to enable better detection of
diseases such as cancer and Alzheimer's, contamination in
industrial manufacture and explosives in aviation settings.
In CBRN detection, the Group provides nuclear radiation
detection solutions to the global homeland defence and security
market. Kromek's compact, handheld, high-performance radiation
detectors, based on advanced scintillation and solid-state readout
technology, are primarily used to protect critical infrastructure,
events, personnel and urban environments from the threat of 'dirty
bombs'.
The Group is also developing bio-security solutions in the CBRN
detection segment. These consist of fully automated and autonomous
systems to detect a wide range of airborne pathogens.
Kromek is listed on AIM, a market of the London Stock Exchange,
under the trading symbol 'KMK'.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAKFLFFXKLZBBD
(END) Dow Jones Newswires
September 12, 2023 02:00 ET (06:00 GMT)
Kromek (LSE:KMK)
Historical Stock Chart
From Dec 2024 to Jan 2025
Kromek (LSE:KMK)
Historical Stock Chart
From Jan 2024 to Jan 2025
